Global Pain Therapeutics Market Leading Companies will have the Highest Market Share by 2023
Jul 7, 2017
Orbis Research Market brilliance released a new research report of 147 pages on title ‘Global Pain Therapeutics Market to 2023-Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse’ with detailed analysis, forecast and strategies.
Dallas, United States - July 7, 2017 /MarketersMedia/ —
The Pain Therapeutics Market covers the drugs used for the relief of acute and chronic pain. This market has long been characterized by high levels of generic revenue, derived largely from opioids, which see high levels of usage worldwide and particularly within the US.
However, the last decade has seen the addition of new premium products to the market, including a wave of drugs approved for the treatment of neuropathic pain conditions - a patient population that previously had very poor treatment options. This influx of premium products is forecast to continue through to 2023.
The causes of the resurgence of premium analgesics are multi-faceted, but the primary driver is to meet the many unmet needs of the market, such as the treatment of neuropathic pain and migraines, and the need to limit the risk of abuse associated with many analgesics, primarily opioids. The revived interest in this market has led to a very high frequency of licensing deals for pain products over the past decade.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/342991 .
Scope
- The pain therapeutics market is forecast to reach $28.8 billion in 2023. What are the key market segments driving this growth?
- The pipeline contains over 800 products. What molecule types and molecular targets are in the pipeline? What are the commercial prospects of promising late stage products?
- Despite historical high levels of generic drug development, there is a very high proportion of novel drugs in the pipeline. How do failure rates, clinical trial size and clinical trial duration differ by indication and molecular target?
- Which of the leading companies will have the highest market share by 2023? Which new companies will enter the market?
- What licensing and co-development deals have occurred within this therapy area since 2006?
Reasons to buy
- Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the pain therapeutics market, in the context of the overall pipeline and current market landscape. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include neuropathic pain, inflammatory pain (including osteoarthritis pain) and migraine.
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyse the pain therapeutics pipeline through a comprehensive review, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at pain therapeutics clinical trials, to provide an insight into the risk associated with attempting to bring pipeline analgesics to market.
- Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
- Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from pain therapeutic products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Assess the licensing and co-development deal landscape for pain therapies.
Buy a report @ http://www.orbisresearch.com/contact/purchase/342991
Related Report By:
Pain Drug Development Pipeline Review, 2017
http://www.orbisresearch.com/reports/index/pain-drug-development-pipeline-review-2017
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Name: Hector Costello
Organization: Orbis Research
Address: 144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A.
Phone: +912064101019
For more information, please visit http://www.orbisresearch.com/reports/index/global-pain-therapeutics-market-to-2023-innovative-new-products-to-address-unmet-need-within-chronic-pain-and-migraine-and-tackle-opioid-abuse
Source: MarketersMedia
Release ID: 215402
More News
Pick Another Protein? Americans Still Want Beef, Despite the Price.
After chicken, consumers are buying more beef, while pork, turkey and soy products remain flat.
The U.S. Becomes a Global Hub for Horse Racing
More horses from overseas are competing in America’s marquee events, as the sport enjoys a renaissance.
Why Did So Many People File Early for Social Security Last Year?
Experts point to well-publicized turmoil at the government agency last year as a potential spark.
Strengthening party self-governance and integrity for economic growth
The 20th Central Committee of the Communist Party of China convened its fifth plenary session in Beijing from October 26 to 29, 2026, where it deliberated and adopted the Resolution of the Central Committee of the Communist Party of China on Certain Major Issues concerning Persevering with Full and Rigorous Party Self-Governance.
70 years on, why global buyers keep coming back to Canton Fair
70 years on, why global buyers keep coming back to Canton Fair
China's manufacturing PMI at 49.3, non-manufacturing PMI at 49.7
China's purchasing managers' index for the manufacturing sector came in at 49.3 in October, down 0.8 percentage points from the previous month, while the non-manufacturing PMI stood at 49.7, down 0.5 percentage points.
How One Country Became the Unlikely Crossroads of the Global A.I. Boom
In Malaysia, U.S. and Chinese tech giants are pouring billions into vast data centers, straining local resources and testing the limits of Washington’s restrictions on advanced chips.
Wanted: New Central Bank Chief. Expertise and Political Acumen Required.
The looming departure of the European Central Bank’s president, Christine Lagarde, has set in motion a high-stakes search for her successor.
Hainan's digital reporting system streamlines grassroots governance
Hainan's digital reporting system streamlines grassroots governance
Big Tech’s Data Center Blitz Is Burning Through Cash and Scaring Wall St.
Amazon became the latest tech company to announce swelling investments in A.I. amid stumbling share prices.
Obamacare Policies Hit Again With Steep Premium Increases for 2027
Premiums will increase an average 13 percent next year for millions of Americans, on top of an earlier steep increase. It adds to the problems facing the program, which the Trump administration has weakened.
Soaring cost of Halloween treats spooks shoppers
The price of candy, especially chocolate, is up, and Halloween bargain hunters are searching for deals and ways to cut costs.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.